Sugi Predict

Sugi Predict / Targets / LIMK1

LIMK1

LIM domain kinase 1 · P53667 · LIMK1 on Sugi Atlas →

120,885 patent compounds predicted against LIMK1, 70,682 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL38544 SCHEMBL38544 0.72 9/20
SCHEMBL231766 SCHEMBL231766 0.79 6/20
SCHEMBL259291 SCHEMBL259291 0.66 6/20
SCHEMBL126242 SCHEMBL126242 0.37 5/20
SCHEMBL232042 SCHEMBL232042 1.00 4/20
SCHEMBL233442 SCHEMBL233442 0.75 4/20
SCHEMBL95142 SCHEMBL95142 1.00 3/20
SCHEMBL233874 SCHEMBL233874 0.79 3/20
SCHEMBL94964 SCHEMBL94964 0.79 3/20
SCHEMBL171201 SCHEMBL171201 0.69 3/20
SCHEMBL11742 SCHEMBL11742 0.66 3/20
SCHEMBL58313 SCHEMBL58313 0.59 3/20
SCHEMBL58543 SCHEMBL58543 0.57 3/20
SCHEMBL60464 SCHEMBL60464 0.57 3/20
SCHEMBL275822 SCHEMBL275822 0.55 3/20
SCHEMBL58550 SCHEMBL58550 0.55 3/20
SCHEMBL59884 SCHEMBL59884 0.54 3/20
SCHEMBL65790 SCHEMBL65790 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL58421) 0.52 3/20
SCHEMBL279552 SCHEMBL279552 0.51 3/20

Clinical trials — most relevant to LIMK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lithium for Prevention of Cognitive Declining in Mood Illnesses PHASE4NOT_YET_RECRUITING
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Trial of Metformin in Individuals With Fragile X Syndrome PHASE2/PHASE3COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention PHASE2NOT_YET_RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Immune Cell Response to Stimuli nanRECRUITING
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? nanUNKNOWN
The Activation of Hippo Pathway in Nasal Polyps nanUNKNOWN
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Profiling Gingival Crevicular Fluid β-Catenin Level With 8-OHdG and Total Antioxidants Capacity During Healing of Periodontal Pockets: A 3-month Clinical Trial nanNOT_YET_RECRUITING
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LIMK1 binder may also engage these)

ProteinNameSimilarity
P53669 — 1.000 P53669 →
P53668 — 1.000 P53668 →
Q8QFP8 — 0.997 Q8QFP8 →
O54785 — 0.993 O54785 →
LIMK2 LIM domain kinase 2 0.991 landscape →
P53666 — 0.990 P53666 →
O42565 — 0.989 O42565 →
P53670 — 0.985 P53670 →
Q32L23 — 0.983 Q32L23 →
ARAF Serine/threonine-protein kinase A-Raf 0.981 landscape →
P34908 — 0.979 P34908 →
O19004 — 0.977 O19004 →
P00542 — 0.977 P00542 →
P14056 — 0.976 P14056 →
P04627 — 0.976 P04627 →
A7E3S4 — 0.976 A7E3S4 →
Q5R5M7 — 0.975 Q5R5M7 →
PLK2 Serine/threonine-protein kinase PLK2 0.975 landscape →
P09560 — 0.974 P09560 →
P00541 — 0.974 P00541 →
Q04982 — 0.974 Q04982 →
Q9EQJ9 — 0.974 Q9EQJ9 →
Q5R4L1 — 0.973 Q5R4L1 →
Q91XL2 — 0.973 Q91XL2 →
Q5F488 — 0.973 Q5F488 →
P27966 — 0.973 P27966 →
Q99N57 — 0.973 Q99N57 →
F1QGZ6 — 0.973 F1QGZ6 →
P11345 — 0.973 P11345 →
Q9R012 — 0.973 Q9R012 →